0001062993-23-017435.txt : 20230901
0001062993-23-017435.hdr.sgml : 20230901
20230901164138
ACCESSION NUMBER: 0001062993-23-017435
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230901
DATE AS OF CHANGE: 20230901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FLOWERS KIRSTEN
CENTRAL INDEX KEY: 0001797209
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41403
FILM NUMBER: 231233107
MAIL ADDRESS:
STREET 1: C/O KURA ONCOLOGY, INC.
STREET 2: 12730 HIGH BLUFF DRIVE, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Comera Life Sciences Holdings, Inc.
CENTRAL INDEX KEY: 0001907685
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 874706968
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12 GILL STREET
STREET 2: SUITE 4650
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (617)871-2101
MAIL ADDRESS:
STREET 1: 12 GILL STREET
STREET 2: SUITE 4650
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2023-08-31
0001907685
Comera Life Sciences Holdings, Inc.
CMRA
0001797209
FLOWERS KIRSTEN
C/O COMERA LIFE SCIENCES HOLDINGS, INC.
12 GILL STREET, SUITE 4650
WOBURN
MA
01801
1
0
0
0
0
Stock Option (Right to Purchase)
0.6995
2023-08-31
4
A
0
67172
0
A
2023-08-31
2033-08-10
Common Stock
67172
67172
D
The option grant was approved by the registrant's board of directors on August 10, 2023, subject to stockholder approval of an amendment to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan (the "Plan") under which the option was granted. The registrant's stockholders approved the Plan amendment on August 31, 2023.
The options became fully vested on the date the Plan amendment was approved by the registrant's stockholders.
In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended June 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,375. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
2023-09-01